This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Steglatro
  • /
  • Ertugliflozin vs. Glimepiride in Type 2 Diabetes M...
Clinical trial

Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)

Read time: 1 mins
Last updated:16th Dec 2013
Identifier: NCT01999218

This study will evaluate the efficacy and safety of the addition of ertugliflozin (MK-8835/PF-04971729) compared with the addition of glimepiride in participants with T2DM who have inadequate glycemic control on metformin. The duration of the trial will be up to approximately 122 weeks. This will include a 1-week screening period, an up to 13-week wash-off/titration/dose stabilization period, a 2-week placebo run-in period, a 104-week double-blind, active comparator-controlled treatment period, and a post-treatment telephone contact 14 days after the last dose of study drug. The primary hypothesis of this study is that after 52 weeks, the change from baseline in hemoglobin A1c (A1C) in participants treated with the addition of ertugliflozin 15 mg once daily is non-inferior compared with that in participants treated with the addition of glimepiride.

Study Type: Interventional  (Clinical Trial)
Actual Enrollment: 1326 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Ertugliflozin (MK-8835/PF-04971729) Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin
Actual Study Start Date: December 16, 2013
Actual Primary Completion Date: April 18, 2017
Actual Study Completion Date: April 18, 2017

- Experimental:
Ertugliflozin 5 mg
- Experimental: Ertugliflozin 15 mg
- Active Comparator: Glimepiride up to 8 mg

Category Value
Date last updated at source 2017-06-09
Study type(s) Interventional
Expected enrolment 1326
Study start date 2013-12-16
Estimated primary completion date 2017-04-18

View full details